Metabolic and cardiovascular effects of early insulin glargin prescription: based on data from ORIGIN study

We discuss results of ORIGIN, a multicenter parallel groups study for efficiency assessment of insulin glargin against polyunsaturatedomega-3 fatty acids or placebo regarding cardiovascular and/or mortality risk reduction in patients with impaired fasting glycemia,impaired glucose tolerance or type...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Elena Valer'evna Biryukova, Alexander Sergeevich Ametov, Mikhail Borisovich Antsiferov, Alsu Gafurovna Zalevskaya, Galina Afanas'evna Mel'nichenko, Ashot Musaelovich Mkrtumyan, Marina Vladimirovna Shestakova
Formato:	article
Lenguaje:	EN RU
Publicado:	Endocrinology Research Centre 2012
Materias:	prediabetes diabetes mellitus hypoglycemia oncology onsulin glargin origin study Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/b7e6d26cdbee4110988b38b6e29a334f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b7e6d26cdbee4110988b38b6e29a334f
record_format	dspace
spelling	oai:doaj.org-article:b7e6d26cdbee4110988b38b6e29a334f2021-11-14T09:00:17ZMetabolic and cardiovascular effects of early insulin glargin prescription: based on data from ORIGIN study2072-03512072-037810.14341/2072-0351-6092https://doaj.org/article/b7e6d26cdbee4110988b38b6e29a334f2012-09-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/6092https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378We discuss results of ORIGIN, a multicenter parallel groups study for efficiency assessment of insulin glargin against polyunsaturatedomega-3 fatty acids or placebo regarding cardiovascular and/or mortality risk reduction in patients with impaired fasting glycemia,impaired glucose tolerance or type 2 diabetes mellitus (T2DM) on its early stage and high risk for cardiovascular events. 12 537 patientstook part in this study; 6 264 were randomized in insulin glargin group, where dosage was adjusted for complete compensationof fasting glycemia (5.3 mmol/l was set as a therapeutic goal). After treatment with glargin therapeutic goal was achieved and furthermaintained for 6.2 years of follow-up. Compensation of fasting glycemia did not affect the outcome of cardiovascular diseases in patientswith early stages of dysglycemia according to primary endpoints. It was not associated with increase in general morbidity and inrisk of hypoglycemic events. Treatment with insulin glargin delayed progression from prediabetes to clinical onset for 28% (OR 0.72,CI 95% 0.58-0.91; p = 0,006), while lowering incidence of DM. Longtime treatment with insulin glargin does not increase incidenceof malignant tumors of different localization, including patients with prediabetes. Due to results of ORIGIN, insulin glargin (Lantus?)has become the most studied human insulin analogue to date.Elena Valer'evna BiryukovaAlexander Sergeevich AmetovMikhail Borisovich AntsiferovAlsu Gafurovna ZalevskayaGalina Afanas'evna Mel'nichenkoAshot Musaelovich MkrtumyanMarina Vladimirovna ShestakovaEndocrinology Research Centrearticleprediabetesdiabetes mellitushypoglycemiaoncologyonsulin glarginorigin studyNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 15, Iss 3, Pp 92-100 (2012)
institution	DOAJ
collection	DOAJ
language	EN RU
topic	prediabetes diabetes mellitus hypoglycemia oncology onsulin glargin origin study Nutritional diseases. Deficiency diseases RC620-627
spellingShingle	prediabetes diabetes mellitus hypoglycemia oncology onsulin glargin origin study Nutritional diseases. Deficiency diseases RC620-627 Elena Valer'evna Biryukova Alexander Sergeevich Ametov Mikhail Borisovich Antsiferov Alsu Gafurovna Zalevskaya Galina Afanas'evna Mel'nichenko Ashot Musaelovich Mkrtumyan Marina Vladimirovna Shestakova Metabolic and cardiovascular effects of early insulin glargin prescription: based on data from ORIGIN study
description	We discuss results of ORIGIN, a multicenter parallel groups study for efficiency assessment of insulin glargin against polyunsaturatedomega-3 fatty acids or placebo regarding cardiovascular and/or mortality risk reduction in patients with impaired fasting glycemia,impaired glucose tolerance or type 2 diabetes mellitus (T2DM) on its early stage and high risk for cardiovascular events. 12 537 patientstook part in this study; 6 264 were randomized in insulin glargin group, where dosage was adjusted for complete compensationof fasting glycemia (5.3 mmol/l was set as a therapeutic goal). After treatment with glargin therapeutic goal was achieved and furthermaintained for 6.2 years of follow-up. Compensation of fasting glycemia did not affect the outcome of cardiovascular diseases in patientswith early stages of dysglycemia according to primary endpoints. It was not associated with increase in general morbidity and inrisk of hypoglycemic events. Treatment with insulin glargin delayed progression from prediabetes to clinical onset for 28% (OR 0.72,CI 95% 0.58-0.91; p = 0,006), while lowering incidence of DM. Longtime treatment with insulin glargin does not increase incidenceof malignant tumors of different localization, including patients with prediabetes. Due to results of ORIGIN, insulin glargin (Lantus?)has become the most studied human insulin analogue to date.
format	article
author	Elena Valer'evna Biryukova Alexander Sergeevich Ametov Mikhail Borisovich Antsiferov Alsu Gafurovna Zalevskaya Galina Afanas'evna Mel'nichenko Ashot Musaelovich Mkrtumyan Marina Vladimirovna Shestakova
author_facet	Elena Valer'evna Biryukova Alexander Sergeevich Ametov Mikhail Borisovich Antsiferov Alsu Gafurovna Zalevskaya Galina Afanas'evna Mel'nichenko Ashot Musaelovich Mkrtumyan Marina Vladimirovna Shestakova
author_sort	Elena Valer'evna Biryukova
title	Metabolic and cardiovascular effects of early insulin glargin prescription: based on data from ORIGIN study
title_short	Metabolic and cardiovascular effects of early insulin glargin prescription: based on data from ORIGIN study
title_full	Metabolic and cardiovascular effects of early insulin glargin prescription: based on data from ORIGIN study
title_fullStr	Metabolic and cardiovascular effects of early insulin glargin prescription: based on data from ORIGIN study
title_full_unstemmed	Metabolic and cardiovascular effects of early insulin glargin prescription: based on data from ORIGIN study
title_sort	metabolic and cardiovascular effects of early insulin glargin prescription: based on data from origin study
publisher	Endocrinology Research Centre
publishDate	2012
url	https://doaj.org/article/b7e6d26cdbee4110988b38b6e29a334f
work_keys_str_mv	AT elenavalerevnabiryukova metabolicandcardiovasculareffectsofearlyinsulinglarginprescriptionbasedondatafromoriginstudy AT alexandersergeevichametov metabolicandcardiovasculareffectsofearlyinsulinglarginprescriptionbasedondatafromoriginstudy AT mikhailborisovichantsiferov metabolicandcardiovasculareffectsofearlyinsulinglarginprescriptionbasedondatafromoriginstudy AT alsugafurovnazalevskaya metabolicandcardiovasculareffectsofearlyinsulinglarginprescriptionbasedondatafromoriginstudy AT galinaafanasevnamelnichenko metabolicandcardiovasculareffectsofearlyinsulinglarginprescriptionbasedondatafromoriginstudy AT ashotmusaelovichmkrtumyan metabolicandcardiovasculareffectsofearlyinsulinglarginprescriptionbasedondatafromoriginstudy AT marinavladimirovnashestakova metabolicandcardiovasculareffectsofearlyinsulinglarginprescriptionbasedondatafromoriginstudy
_version_	1718429606883622912

Metabolic and cardiovascular effects of early insulin glargin prescription: based on data from ORIGIN study

Ejemplares similares